Remed uses 99.89% of KRW 2 billion share buyback trust contract

Remed acquired 631,362 shares (total cost approx. KRW 1.998 billion, 99.89% of contract amount) under a KRW 2 billion share buyback trust contract signed on Feb 9, 2026, as of May 11, 2026.
This represents 2.04% of total outstanding shares (30,907,150).
Trust contract period: Feb 9, 2026 to Aug 8, 2026, with Shinhan Investment Corp.
No change in largest shareholder Lee Keun-yong's holdings (8,110,000 shares).

ADVERTISEMENT (250px+)